Brief: Avacta Therapeutics Says Cardiac Dosing Limit Removed In Faridoxorubicin Program
03/02/2026 07:15
Feb 3 (Reuters) - Avacta Group PLC AVCT.L: AVACTA GROUP PLC - FARIDOXORUBICIN PROGRAM CLINICAL UPDATES AVACTA THERAPEUTICS - CARDIAC DOSING LIMIT REMOVED IN FARIDOXORUBICIN PROGRAM Source text: ID:nRSC4824Ra Further company coverage: AVCT.L ((Reuters.Briefs@thomsonreuters.com))